Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin - Wikidata - wikimedia - TriplyDB

Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin

Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin

http://www.wikidata.org/entity/Q28475626

about

Immunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantation Clinical Potential of Regulatory T Cell Therapy in Liver Diseases: An Overview and Current Perspectives Tolerance in liver transplantation: Biomarkers and clinical relevance Inflammation-driven reprogramming of CD4+ Foxp3+ regulatory T cells into pathogenic Th1/Th17 T effectors is abrogated by mTOR inhibition in vivo Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease Low dose rapamycin exacerbates autoimmune experimental uveitis Interface of signal transduction inhibition and immunotherapy in melanoma.Induction of granzyme B expression in T-cell receptor/CD28-stimulated human regulatory T cells is suppressed by inhibitors of the PI3K-mTOR pathway.Immunologic effects of rituximab on the human spleen in immune thrombocytopenia.The role of the thymus in tolerance.mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus?Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus.Insight into the role of mTOR and metabolism in T cells reveals new potential approaches to preventing graft rejection.A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy.Rapamycin increases the yield and effector function of human γδ T cells stimulated in vitro.Artemisinin analogue SM934 ameliorates murine experimental autoimmune encephalomyelitis through enhancing the expansion and functions of regulatory T cell.Generation of human regulatory T cells de novo with suppressive function prevent xenogeneic graft versus host disease.An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness.Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation mTOR and metabolic regulation of conventional and regulatory T cells.Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly.Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg.In Vivo Induction of Functionally Suppressive Induced Regulatory T Cells from CD4+CD25- T Cells Using an Hsp70 Peptide.Murine regulatory T cells contain hyperproliferative and death-prone subsets with differential ICOS expression.Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells.Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.Regulation and function of mTOR signalling in T cell fate decisions.The STAT5b Pathway Defect and Autoimmunity Preparation of myeloid derived suppressor cells (MDSC) from naive and pancreatic tumor-bearing mice using flow cytometry and automated magnetic activated cell sorting (AutoMACS).Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4(+)CD25(+)FOXP3(+) T regulatory cell subpopulations Comparison of regulatory T cells in hemodialysis patients and healthy controls: implications for cell therapy in transplantation.T cell Receptor Signal Transduction in T lymphocytes.Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host disease Relative resistance of human CD4(+) memory T cells to suppression by CD4(+) CD25(+) regulatory T cells.Anti-CD20 as the B-Cell Targeting Agent in a Combined Therapy to Modulate Anti-Factor VIII Immune Responses in Hemophilia a Inhibitor Mice Regulatory T cells as therapeutic targets in rheumatoid arthritis.The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism

P2860

Q26751433-DB38F3B1-4684-4F05-B1FE-7374AEF6E1D0 Q28069832-0EEABE3E-2278-433D-8AFA-4626F05167CC Q28079523-C5FE7D76-9CE2-490D-9F65-0EDD7B6FF603 Q28482490-03A6F6BD-FB22-4687-B95B-30DE71D5F69C Q28601365-FCF6539E-2DFA-4141-8899-7E17C1B25795 Q28730115-773EA25A-A667-4814-9650-5BBB02EDD20E Q30429380-38D59435-747D-456D-BA44-EEF73D4FD2D9 Q30907499-8018E04C-C18E-49BF-BC90-65C23E1ED512 Q33396902-26ED3B71-9509-4808-BAE4-688E49B571DC Q34103905-B2989CB7-7B81-4D08-8EAD-CEC428C06177 Q34107250-162E5C05-A57C-4042-881F-1FF9B6D31E67 Q34138598-B15C6875-7845-43F4-9AD1-8FE322C5C927 Q34316147-2987EA36-272B-4B57-9E26-4258FC069846 Q34361763-621251CA-86BF-40C6-BE90-FD866605AC62 Q34437449-AC22976E-80C4-42E3-9663-CCA808108ACE Q34634834-2B900CDB-26FA-4EB8-81DF-7E7F9004B9FB Q34802235-CF44F9BE-AD05-4CD0-9ADD-551FF8DBD642 Q34979858-D5D40288-6919-4744-982B-460D8AC9696B Q34996186-27479A02-CE04-4846-A4A0-4BCBF6B63A34 Q35097239-08B0F907-0657-4571-AE70-017648DAA915 Q35184589-A977D0FA-7C15-4A7F-A42F-53D2D2B6838F Q35430711-642134DA-C7E7-44F0-B0A3-9659CBE324A2 Q35553381-1EC7AD50-A861-4BAF-AC29-208D3582890F Q35583409-E7376DB4-D572-4FB4-A4F7-710C40F2C5E5 Q35673344-06DBDB0F-897D-4A02-839A-08940973D4E4 Q35740112-B8CAEB4F-32DB-4ED6-9C82-7AD31B9F8727 Q35743830-D1854181-D89C-4856-8DDB-C5EA1D27F9B5 Q35834220-D6B70044-608A-479D-A2A1-BEBDABDF9EDA Q36157753-68257465-4A74-4FF6-8D72-8CCB16ACE6F6 Q36162564-F4B227FA-D63A-4718-859B-DD79977BD5A7 Q36317387-5383A85A-C175-4610-9FDD-9AA897C0EC31 Q37000189-F6D402CD-D503-4429-9051-1B22D9FB9A01 Q37060678-6091CDF2-F449-4BC0-94A6-ACEF01600F6E Q37065658-EB2766D3-E353-4505-BA62-6174560B58BF Q37087575-71519496-D36A-47E1-93D8-C23F98A63FDD Q37202298-45B715AD-8126-47A1-9152-D946A59F2654 Q37274094-14694A17-6470-4DB2-B19A-91B795B94E2B Q37434315-297412E9-4C69-4894-AC9C-856E4BBD6436 Q37607071-ECE3705B-7B4C-4A80-A993-E6B0BD420B28 Q37792556-C49FF21E-CFD4-490C-A3D5-91B1A072DD4E

P2860

Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin

http://www.wikidata.org/entity/Q28475626

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Differential responses of huma ...... effector T cells to rapamycin

@ast

Differential responses of huma ...... effector T cells to rapamycin

@en

Differential responses of huma ...... effector T cells to rapamycin

@nl

type

label

Differential responses of huma ...... effector T cells to rapamycin

@ast

Differential responses of huma ...... effector T cells to rapamycin

@en

Differential responses of huma ...... effector T cells to rapamycin

@nl

prefLabel

Differential responses of huma ...... effector T cells to rapamycin

@ast

Differential responses of huma ...... effector T cells to rapamycin

@en

Differential responses of huma ...... effector T cells to rapamycin

@nl

P1433

Q28475626-EF42C5A5-B634-4719-992E-95F6410358EC

P1476

Q28475626-356EF2E1-AD8B-4D18-A9E1-A441E762EB8F

P2093

Q28475626-46CBD822-3D08-460C-80C0-B70023F324C5

Q28475626-7901C5D3-972A-4D6B-A721-C43CC15929DF

Q28475626-7F98EAD9-BB68-44E5-A26D-A77CB4F13BC6

Q28475626-862FAA76-07BE-4ECC-9F54-FB0506E63540

P2860

Q28475626-0373EE91-197C-460F-897C-AC0A580C47C2

Q28475626-1135425D-3A6A-450B-B632-B0CC1DE04E44

Q28475626-130485E1-77D0-4A02-84A1-A9A66CF2BDF2

Q28475626-1657313F-873A-41D7-9D57-D92D2B90A333

Q28475626-1BB2BAF0-BCFE-4036-8BA0-2DEAAEB7443D

Q28475626-295C362B-E43A-4C80-93CC-BA8B4771F46A

Q28475626-39DEF8FF-881D-450A-99EC-B49DE04E922A

Q28475626-3AC43A78-7402-491A-9461-3B3D5495D47C

Q28475626-4A3489E6-FC98-4792-AD7D-0E7591663B31

Q28475626-4FD3B2C2-2004-431F-8349-EF43DB4D799C

P304

Q28475626-77E0B8E1-079C-45E7-A632-409A5BDC54D5

P31

Q28475626-CCA3BBC6-FB41-4D88-863E-3366DAF69C7B

P3181

Q28475626-ABE41996-5048-44A9-8E68-E1164F7C8A52

P356

Q28475626-16079168-ADD5-4A02-93F4-5DBCEF969EBF

P407

Q28475626-6E16C12A-FAC7-47CD-BC61-6BC84580AA4E

P433

Q28475626-038AECCE-6364-444E-A675-5B9AB87ABABA

P478

Q28475626-93F27697-D14C-42FD-B67F-0775C832239D

P50

Q28475626-147F205D-1AE6-4645-995C-B0B7D4F28A32

P577

Q28475626-FA43853A-53BC-4F96-9C3D-20CEEA9640D8

P5875

Q28475626-16FD6919-30AC-4B9E-B29A-2A1E6B79BD61

P698

Q28475626-315FEBB2-E359-4207-A5D9-E1FAFA38C085

P932

Q28475626-B267AF31-D995-4B3C-9B2B-1D16D4860C1F

P3181

P356

JOURNAL.PONE.0005994

P1433

P1476

Differential responses of huma ...... effector T cells to rapamycin

@en

P2093

Laura Strauss

http://www.w3.org/2001/XMLSchema#string

Magis Mandapathil

http://www.w3.org/2001/XMLSchema#string

Marta Szajnik

http://www.w3.org/2001/XMLSchema#string

Theresa L Whiteside

http://www.w3.org/2001/XMLSchema#string

P2860

Control of regulatory T cell development by the transcription factor Foxp3

Immunopharmacology of rapamycin

A function for interleukin 2 in Foxp3-expressing regulatory T cells

Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia

Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells.

Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy

Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis.

Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling.

FOXP3: not just for regulatory T cells anymore.

Defective regulatory and effector T cell functions in patients with FOXP3 mutations.

P304

e5994

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3655579

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0005994

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Malgorzata Czystowska

P577

2009-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26308084

http://www.w3.org/2001/XMLSchema#string

P698

19543393

http://www.w3.org/2001/XMLSchema#string

P932

2694984

http://www.w3.org/2001/XMLSchema#string